BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/28/2014 5:50:00 PM | Browse: 510 | Download: 310
Publication Name World Journal of Gastroenterology
Manuscript ID 6395
Country of Manuscript Source China
Received
2013-10-16 11:30
Peer-Review Started
2013-10-16 17:42
To Make the First Decision
2013-12-16 17:45
Return for Revision
2013-12-18 10:34
Revised
2014-01-13 16:48
Second Decision
2014-02-27 11:18
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-02-27 11:31
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
2014-03-19 21:23
Typeset the Manuscript
2014-04-14 16:20
Publish the Manuscript Online
2014-04-29 09:53
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Specialty Gastroenterology and Hepatology
Manuscript Type Autobiography
Article Title Entecavir vs lamivudine therapy for naive patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure
Manuscript Source Invited Manuscript
All Author List Yang Zhang, Xiao-Yu Hu, Sen Zhong, Fang Yang, Tao-You Zhou, Guo Chen, Yan-Yan Wang and Jian-Xing Luo
Funding Agency and Grant Number
Funding Agency Grant Number
National Key Technology R&D Program of China during the 10th Five-Year Plan Period 2008ZX10005
National Key Technology R&D Program of China during the 10th Five-Year Plan Period 2009ZX10005
Corresponding author Xiao-Yu Hu, Professor, Department of Infectious Diseases, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, 39 Shierqiao Road, Chengdu 610072, Sichuan Province, China. xiaoyuhu@aliyun.com
Keywords Acute-on-chronic liver failure; Hepatitis B; Entecavir; Lamivudine; Survival
Core Tip This study compared the short-term and long-term efficacy of entecavir and lamivudine in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure (ACLF). Entecavir significantly reduced hepatitis B virus DNA levels, decreased the Child-Turcotte-Pugh and model for end-stage liver disease (MELD) scores, and thereby improved the long-term survival rate in patients with spontaneous reactivation of hepatitis B presenting as ACLF. Pretreatment MELD score and virological response at 30 d were good predictors of long-term survival.
Publish Date 2014-04-29 09:53
Citation Zhang Y, Hu XY, Zhong S, Yang F, Zhou TY, Chen G, Wang YY, Luo JX. Entecavir vs lamivudine therapy for naïve patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. World J Gastroenterol 2014; 20(16): 4745-4752
Url http://www.wjgnet.com/1007-9327/full/v20/i16/4745.htm
DOI http://dx.doi.org/10.3748/wjg.v20.i16.4745
Full Article (PDF) WJG-20-4745.pdf
Full Article (Word) WJG-20-4745.doc
Manuscript File 6395-Review.doc
Answering Reviewers 6395-Answering reviewers.pdf
Copyright License Agreement 6395-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 6395-Language certificate.PDF
Peer-review Report 6395-Peer review(s).pdf
Scientific Editor Work List 6395-Scientific editor work list.doc